Beneficial effect of a novel nonsteroidal anti-inflammatory agent with basic character and antioxidant properties on experimental colitis in rats

Annals of Gastroenterology

Volumn 14, Issue 4, 2001, Pages 293-298

  Andreadou, Ioanna ^a   Papalois, A ^b   Triantafillidis, John K ^c,e   Demonakou, Maria ^d   Govosdis, V ^c   Vidali, Maria ^c   Anagnostakis, E ^c   Kourounakis, P N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ELPEN Pharmaceuticals   (Greece)

^c Saint Panteleimon General State Hospital   (Greece)

^d SISMANOGLIO HOSPITAL   (Greece)

^e NONE   (Greece)

Author keywords

Antioxidant; Basic anti inflammatory agent; Experimental colitis; Methylprednisolone; Non steroidal antiinflammatory drugs; Treatment

Indexed keywords

5 (2 HYDROXYETHYLAMINO) 1 CYCLOHEXYL 2 PENTANONE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RAT; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS;

EID: 34548316977     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Nassif A, Longo WE, Mazuski JE, Vernava AM, Kaminski DL. Role of cytokines and platelet-activating factor in inflammatory bowel disease. Dis Colon Rectum, 1996; 39:217-223.
2. Boughton-Smith N, Pettipher R. Lipid mediators and cytokines in inflammatory bowel disease. Eur J Gastroenterol Hepatol, 1990; 2:241.
3. Buch E, Hinojosa J, Lledo S, Bulbena O, Navarro C, Fernandez C. Transmucosal potential difference in experimental colitis in rats. Inflammation, 1995; 19:445-455.
4. Andreadou I, Rekka EA, Demopoulos VJ, Bijloo GJ, Kourounakis PN. (1997) Synthesis, antioxidant and anti-inflammatory activity of novel substituted ethylenediamines and ethanolamines. A preliminary quantitative structure-activity relationship study. Arzneim-Forsch/ Drug Res, 1997; 47:643-647.
5. Morris GP, Beck PL, Herridde MS, Depew Wr, Szwczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration of the rat colon. Gastroenterology, 1989; 96:795-803.
6. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiave. J Clin Pathol 1997; 50,93-105.
7. Geboes K, Ridell R, Ost A, Persson T, Lotberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47:404-409.
8. Andreadou I, Rekka E, Demopoulos VJ, Kourounakis PN. Effect of some novel ethylenediamine and ethanolamine derivatives on carrageenan induced inflammation. Correlation with antioxidant activity and structural characteristics. Res Com Chem Pathol Pharmacol 1992; 78:245-248.
9. Wolfe MM, Lichtenstein DR, Singh, G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med 1999; 17:1888-1899.
10. Nieto N, Torres NU, Fernandez W, et al. Experimental ulcerative colitis impairs antioxidant defense system in rat intestine. Dig Dis Sci 2000; 45:1820-1827.
11. Lesch CA, Kraus ER, Sanchez B, Gilbertsen R, Guglietta A. Lack of beneficial effect of COX-2 in an experimental model of colitis. Methods Find Exp Clin Pharmacol 1999; 21:99-104.
12. Guo Y, Liu ES, Ko JK et al. Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. Eur J Pharmacol 2001; 411:193-203.
13. Karmeli F, Cohen P, Rachmilewitz D. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur J Gastroenterol Hepatol 2000; 12:223-231.
14. Kaya E, Gur ES, Ozguc H, Bayer A, Tokyay R. L-glutamine enemas attenuate mucosal injury in experimental colitis. Dis Colon Rectum 1999; 42:1209-1215.
15. Boirivant M, Fuss IJ, Ferroni L, De Pascale M, Srober W. Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis. J Immunol 2001; 166:3522-3532.
16. Cuzzocrea S, McDonald MC, Mazzon E, et al. Calpain A inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. Gut 2001; 48:478-488.
17. Louis E. The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: characterisation, genetics and clinical application. Focus on TNF alpha. Acta Gastroeneterol Belg 2001; 64:1-5.
18. Worledge KL, Godiska R, Barrett TA, Kink JA. Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Dig Dis Sci 2000; 45:2298-2305.
19. Kourounakis P.N., Tsiakitzis K., Kourounakis A.P., Galanakis D. Reduction of gastrointestinal toxicity of NSAIDs via molecular modifications leading to antioxidant anti-inflammatory drugs. Toxicology 2000; 144:205-210.
20. Yoshida N, Yoshikawa T, Yamaguchi T, et al. A novel water soluble vitamin E derivative protects against experimental colitis in rats. Antioxidant Redox Signal, 1999; 1:555-562.